51784-03-3

Basic information

• Product Name: 2-PIPERIDIN-4-YL-BENZOOXAZOLE
• Synonyms: OTAVA-BB BB7020410137;CHEMBRDG-BB 4003380;BUTTPARK 90\08-60;AKOS BBS-00005830;2-PIPERIDIN-4-YL-BENZOOXAZOLE;2-PIPERIDIN-4-YL-1,3-BENZOXAZOLE;2-(4-PIPERIDINYL)-1,3-BENZOXAZOLE;2-piperidin-4-yl-1,3-benzoxazole(SALTDATA: FREE)
• CAS NO: 51784-03-3
• Molecular Formula: C₁₂H₁₄N₂O
• Molecular Weight: 202.25
• Mol File: 51784-03-3.mol

Chemical Properties

• Melting Point: 114-116°C
• Boiling Point: 331.6 °C at 760 mmHg
• Flash Point: 154.3 °C
• Appearance: /
• Density: 1.143 g/cm³
• Vapor Pressure: 0.000154mmHg at 25°C
• Refractive Index: 1.582
• PKA: 9.87±0.10(Predicted)
• CAS DataBase Reference: 2-PIPERIDIN-4-YL-BENZOOXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PIPERIDIN-4-YL-BENZOOXAZOLE(51784-03-3)
• EPA Substance Registry System: 2-PIPERIDIN-4-YL-BENZOOXAZOLE(51784-03-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 51784-03-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H14N2O/c1-2-4-11-10(3-1)14-12(15-11)9-5-7-13-8-6-9/h1-4,9,13H,5-8H2

Upstream product

• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 95-55-6 2-amino-phenol 
• 100-39-0 benzyl bromide 
• 2295-47-8 2-(pyridin-4-yl)benzoxazole 
• 498-94-2 isonipecotic acid 

Downstream Products

• 199329-00-5 4-(Benzoxazol-2-yl)-1-benzyl-1,2,3,6-tetrahydropyridine hydrogen oxalate 
• 295789-95-6 C₂₂H₂₇N₃O₃S 
• 1026272-98-9 2-(1-{3-[2-(4-Fluoro-phenyl)-[1,3]dioxolan-2-yl]-propyl}-piperidin-4-yl)-benzooxazole 
• 1596340-61-2 2-(1-(5-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)pentyl)piperidin-4-yl)benzo[d]oxazole 
• 1596340-59-8 2-(1-(4-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)butyl)piperidin-4-yl)benzo[d]oxazole 
• 1596340-57-6 2-(1-(3-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)propyl)piperidin-4-yl)benzo[d]oxazole 
• 1159096-86-2 C₂₅H₂₂N₂O₂ 

Relevant articles and documents

Chemical synthesis and molecular modeling of novel substituted N-1,3-benzoxazol-2yl benzene sulfonamides as inhibitors of inhA enzyme and Mycobacterium tuberculosis growth

Abstract: Tuberculosis (TB) is one of the major contagious diseases with high mortality which is caused by Mycobacterium tuberculosis (Mtb) pathogen. Due to the existing antibiotic resistance (MDR-TB) to tuberculosis, the demand for the development of new potential chemotherapy drugs is increasing. Herein, we report synthesis of two novel benzoxazole-based series, namely 2-phenyl benzoxazole sulfonamide and 2-piperidine-benzoxazole sulfonamides. These compounds were evaluated for their antimycobacterial activity against Mycobacterium tuberculosis H37Rv strain, using the microplate alamarBlue assay. Molecular docking studies were carried out to comprehend the binding mode of the compounds. It is evident from molecular docking studies and minimum inhibitory concentration assay (MIC) that 2-phenyl benzoxazole sulfonamide scaffold has a greater potential of antitubercular activity possibly by ENR inhibition (inhA inhibitors). In silico cytotoxicity studies using CLC-Pred tool database suggested that both the series were relatively safe. Graphic abstract: [Figure not available: see fulltext.].

Benzdioxan-benzocarbazoles oxa (thia) azole piperidine derivatives and its use

The present invention belongs to the field of pharmaceutical chemistry, and particularly to a benzodioxane-benzoxazole (benzothiazole) piperidine derivative and an application thereof. According to the present invention, the benzodioxane-benzoxazole (benzothiazole) piperidine derivative is a compound represented by a general formula (I) or a medically acceptable salt thereof; and in vitro receptor binding test results show that the compound represented by the general formula (I) or the medically acceptable salt thereof provides high affinity for a 5-HT1A receptor and a 5-HT2A receptor, and animal test results show that the mouse immobility time can be significantly reduced when the compound is used in acute treatment, such that the compound provides treatment effects for neuropsychiatric diseases, particularly depression. The general formula (I) is as the follow.

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS

Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.

Sulfonamide derivatives as 5-HT7 receptor antagonists

The invention relates to novel sulfonamide compounds having 5-HT7receptor antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders. wherein: Q is phenyl or thienyl; R1is halogen, hydroxy, C1-6alkyl, CF3, OCF3or C1-6alkoxy; m is 0, 1, 2 or 3; R2is C1-4alkyl; X is carbon or CH, is a single bond when X is nitrogen or CH or is a double bond when X is carbon, D is a single bond, C═O, O or CH2subject to the proviso that when X is nitrogen then D is not oxygen; P is a 5 or 6 membered heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a benzofused heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur; R3is C1-6alkyl optionally substituted by NR4R5, aryl, arylC1-6alkyl, C1 6alkoxy, C1-6alkylthio, cyano, hydroxy, nitro, halogen, CF3, C2F5, NR4R5, CONR4R5, NR4COR5, S(O)pNR4R5, CHO, OCF3, SCF3, CH2OR6, CO2R6or COR6where p is 0, 1 or 2 and R4, R5and R6are independently hydrogen, C1-6alkyl, aryl or arylC1-6alkyl; n is 0, 1, 2 or 3.

Serotonin 5-HT3 receptor partial activator

This invention provides a serotonin 5-HT3 receptor partial activator which has a serotonin 5-HT3 receptor activating action, in addition to its serotonin 5-HT3 receptor antagonism, and does not cause constipation as a side effect. Particularly, based on the finding that newly synthesized benzoxazole derivatives typified by the compounds of the following formula (2) have strong serotonin 5-HT3 receptor antagonism and serotonin 5-HT3 receptor activating action, this invention provides these benzoxazole derivatives as serotonin 5-HT3 receptor partial activators. In the above formula, R1 to R4 may be the same or different from one another and each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group or a substituted or unsubstituted amino group, or two groups of R1 and R2 may be linked together to form a ring structure, namely benzene ring; R5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group or a substituted or unsubstituted lower alkenyl group; and m is an integer of 1 to 4.

(Azetidin-1-ylalkyl) lactams as tachykinin antagonists

The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein R is C3 -C7 cycloalkyl, aryl or C1 -C6 alkyl, said C1 -C6 alkyl, said C1 -C6 alkyl being optionally substituted by fluoro, COOH, --COO(C1 -C4 alkyl), C3 -C7 cycloalkyl, adamantyl, aryl or het1, and said C3 -C7 cycloalkyl being optionally substituted by 1 or 2 substituents each independently selected from C1 -C4 alkyl, C3 -C7 cycloalkyl, C1 -C4 alkoxy, hydroxy, fluoro, fluoro (C1 -C4) alkyl and fluoro (C1 -C4) Alkoxy; R1 is phenyl, naphthyl, thienyl, benzothienyl or indolyl, each optionally substituted by 1 or 2 substituents each independently selected from C1 -C4 alkyl, C1 -C4 alkoxy, halo and trifluormethyl; R2 is --CO2 H, --CONR3 R4, --CONR5 (C3 -C7 cycloalkyl), --NR5 (C2 -C5 alkanoyl), --NR3 R4, --NR5 CONR5 R6, (C3 -C7 cycloalkyl-C1 -C4 alkyl)R5 N--, --NR5 COCF3, --NR5 SO2 CF3, --NR5 (SO2 C1 -C4 alkyl), --NR5 SO2 NR5 R6, --NR5 (SO2 aryl), --N(aryl) (SO2 C1 -C4 alkyl), --OR5, --O(C3 -C7 cycloalkyl), --SO2 NR5 R6, het3 or a group of formulas: (a), (b), (c), (d), (e), (f), (g) or (h); X is C1 -C4 alkylene; X1 is a direct link or C1 -C6 alkylene; X2 is a direct link, CO, SO2, or NR5 CO; and m is 0, 1 or 2; together with intermediates used in the preparation of compositions containing and the use as tachykinin angatonists of such derivatives. STR1

Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut

A series of benzoxazoles with a nitrogen-containing heterocyclic substituent at the 2-position was prepared and evaluated for 5-HT3 partial agonist activity on isolated guinea pig ileum. The nature of the substituent at the 5-position of the benzoxazole ring affected the potency for the 5-HTs receptor, and the 5-chloro derivatives showed increased potency and lowered intrinsic activity. 5-Chloro-7-methyl-2-(4-methyl-1- homopiperazinyl)benzoxazole (6v) exhibited a high binding affinity in the same range as that of the 5-HT3 antagonist granisetron, and its intrinsic activity was 12% of that of 5-HT. Compound 6v inhibited 5-HT-evoked diarrhea but did not prolong the transition time of glass beads in the normal distal colon even at a dose of 100 times the ED50 for diarrhea inhibition in mice. Compounds of this type are expected to be effective for the treatment of irritable bowel syndrome without the side effect of constipation.

Synthesis and structure-activity relationship of new piperidinyl and piperazinyl derivatives as antiallergics

A series of piperazinebenzothiazoles 3-5, piperazinebenzimidazoles 6-12, piperidinobenzothiazoles 14-45, piperidinobenzoxazoles 46-52 and piperidinobenzimidazoles 53-129 has been synthesized and their antiallergic activity evaluated by means of the passive cutaneous anaphylaxis (PCA) assay. Structure-activity relationships are discussed and related to classical antihistaminics. Piperidino derivatives with an aryl group linked to the nitrogen atom by an ethyl chain are the most active compounds, with ID50 1 mg/kg po. Some of these compounds are more potent antiallergics than astemizole and terfenadine.

Substituted piperidinylpropanols

Compounds having the formula STR1 and the pharmaceutically acceptable salts thereof, wherein n is 0, 1 or 2; R1 is alkanoyl; and R2 is STR2 R3 is alkyl; R4 is cyano or hydroxy; R5 is hydroxy or alkano